Benepali Surge And Imraldi Gains Drive Biogen Biosimilars Past US$500m

With sales climbing by more than two-fifths last year, Biogen expects its biosimilar sales to continue to grow by double digits in 2019, driven by the launch of the Imraldi adalimumab biosimilar in mid-October last year.